IL9

Across TCGA pan-cancer cohorts, IL9 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IL9 data layer compared with 14 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IL9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IL9 expression acts as an unfavorable survival marker.

HNSC, COAD, and LUSC are the cancer types where IL9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.058	0.751	<.001	48	view →
COAD	OS	Median	All	0.001	0.871	<.001	24	view →
LUSC	OS	Median	All	0.011	0.819	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IL9–HNSC (OS)

Open the HNSC breakdown →